Web Development Company in Cambridge

A Cambridge web engagement is priced from the compliance envelope outward. At the simple end is a scoped marketing site or content-led launch at Cambridge rates over eight to fourteen weeks, covering discovery, design, a Next.js, Astro, or SvelteKit build, a headless CMS (Sanity, Contentful, Strapi, Payload, or Storyblok) configured for editorial workflow, WCAG 2.2 AA accessibility audit, Core Web Vitals tuning, and basic analytics; next is a product web application or customer portal with authentication, role-based access, integrations with up to three enterprise systems, and a UK GDPR data flow review; at the top is a regulated pharma medical-affairs platform with ABPI Code compliance, MHRA Blue Guide content controls, healthcare-professional verification, and prescribing-information access management. NHS clinical web interfaces with DTAC, DCB 0129, and DCB 0160 documentation add 15 to 30 percent to scope. Cambridge rates sit above most UK regions because of the ARM and AstraZeneca talent premium and the regulatory depth required for pharma and clinical work. We give fixed-fee proposals and flag HMRC R&D Tax Relief and Patent Box eligibility at scoping.

Yes. ARM's developer portal, Raspberry Pi's documentation and Foundation educational sites, and the broader Silicon Fen developer-experience demand share a profile: deep documentation, code-sample correctness across multiple toolchains, search that actually works on technical content, version-aware navigation across overlapping product lines, and customer-facing portals that respect UK Strategic Export Controls and US Export Administration Regulations for dual-use technology. We build documentation portals on Nextra, Starlight, Docusaurus, or bespoke Next.js with MDX and code-execution sandboxes (StackBlitz, CodeSandbox, or self-hosted equivalents), implement Algolia DocSearch or Typesense for search, version content with proper canonicalisation and hreflang for Cambridge's global audience, and integrate export-control review into the publication workflow rather than as a manual gate. Customer authentication and entitlement for IP licensing portals integrates with the customer's IDP via SAML or OIDC, with audit trails ARM-grade procurement actually inspects.

Pharma medical-affairs and corporate sites face MHRA Blue Guide controls on advertising medicines to healthcare professionals and the public, the ABPI Code of Practice administered by the Prescription Medicines Code of Practice Authority (PMCPA), the EFPIA Code where European audiences are in scope, and ICO oversight of any personal data flows. Our delivery includes content-approval workflow inside the CMS (typically Veeva Vault, Aprimo, or a bespoke headless setup) where medical, legal, and regulatory (MLR) review is enforced before publication, healthcare-professional verification flows that meet the ABPI Code requirements (GMC and PSNI registration lookups, captcha-resistant verification, audit-trailed acceptance of terms), prescribing-information access controls with download audit, and global locale management for sites that serve UK, EU, US, and rest-of-world audiences under different regulatory regimes. Adverse-event reporting links into the client's pharmacovigilance system through a documented data flow. We have shipped to this pattern.

Web interfaces feeding clinical decision-making or sitting inside an NHS workflow have to clear the NHS Digital Technology Assessment Criteria (DTAC) covering clinical safety, data protection, technical assurance, interoperability, and usability. Where the interface meets the legal definition of a medical device we run MHRA software-as-a-medical-device classification (Class I, IIa, IIb, III) and produce a DCB 0129 hazard log maintained by the supplier and a DCB 0160 clinical safety case maintained by the deploying NHS organisation, both signed by a registered clinical safety officer. NHS Information Governance handover includes a Data Security and Protection Toolkit (DSPT) submission, completion of the relevant Data Sharing Agreement, and alignment with NHS England's Cyber Assessment Framework where the interface sits in critical infrastructure. We have shipped to Addenbrooke's and Cambridge University Hospitals teams under this pattern, and our documentation has cleared NHS England digital assurance review without external rework.

Discovery includes a UK GDPR data flow review covering every personal-data process the site touches (analytics, marketing, identity, support, customer service), an ICO data protection impact assessment where processing is large-scale, systematic, or involves special category data, and where the buyer is a public-sector body a PSBAR accessibility and ICO transparency-notice review. We default to UK data residency at AWS eu-west-2, Azure UK South, or GCP europe-west2, document cross-border transfers under UK GDPR Article 46 Standard Contractual Clauses and a Transfer Risk Assessment where unavoidable, and implement cookie consent on Cookiebot, OneTrust, or a bespoke open-source CMP that meets the ICO's 2024 guidance on cookies and PECR (consent before non-essential cookies, easy withdrawal, granular categories, no dark patterns). The implementation is signed off by the client's Data Protection Officer rather than handed over as a checkbox.

The UK Artificial Intelligence (Regulation) Bill, introduced as a Private Member's Bill in the 2024 Parliamentary session and signalled by the Department for Science, Innovation and Technology (DSIT) in the February 2024 White Paper response, proposes a principles-based regime relying on existing regulators (ICO, MHRA, FCA, CMA, Ofcom, HSE) rather than a single horizontal authority. Web projects in Cambridge touch the Bill when they embed AI features (chatbots, recommendation, content generation, automated decision-making). Our scoping classifies the AI features against UK GDPR Article 22 automated decision-making restrictions, applies ICO guidance on AI and data protection, runs a sectoral regulator check (MHRA for clinical, FCA for fintech, EHRC for employment scoring, Ofcom for content moderation at scale), and ships model cards plus explainability documentation where the AI feature is material. We also track the EU AI Act for clients exporting to continental users.

Every Cambridge web build ships against WCAG 2.2 AA as the baseline, aligned with the UK Equality Act 2010 reasonable-adjustments duty and where the buyer is a public-sector body the Public Sector Bodies (Websites and Mobile Applications) Accessibility Regulations 2018 (PSBAR), which require WCAG 2.1 AA conformance and an accessibility statement that meets the EHRC and Government Digital Service requirements. Our delivery includes automated accessibility scanning on every pull request (axe-core, Pa11y, Lighthouse), manual audit by an accessibility specialist against WCAG 2.2 AA at staging, screen-reader testing on VoiceOver, NVDA, and TalkBack, and an accessibility statement published before launch and reviewed annually. For pharma and clinical clients we extend testing to assistive technology used by patients with relevant conditions where the audience demographic requires it.

Most genuinely novel web development qualifies for HMRC R&D Tax Relief. SMEs and large companies now claim under the merged RDEC scheme effective for accounting periods beginning on or after 1 April 2024, replacing the prior SME and RDEC split, with an enhanced rate for R&D intensive SMEs. Eligible activity in web work typically covers algorithmic uncertainty (novel sync patterns, real-time architecture, custom CMS authoring workflows for regulated content, accessibility innovation, performance optimisation against documented Core Web Vitals targets), systematic investigation, and failed-hypothesis work, rather than routine UI integration or known-stack deployment. We deliver time-tracked engineering logs, technical narratives, experiment histories, and uncertainty documentation aligned with the CT600L return and HMRC's revised guidance on software R&D. Where the client patents algorithms or methods through the UK Intellectual Property Office, downstream profits may further qualify for the Patent Box 10 percent corporation tax rate. Final eligibility sits with your R&D tax adviser and HMRC.